$ImmunityBio, Inc.(IBRX)$ $Invesco QQQ(QQQ)$ $SPDR S&P 500 ETF Trust(SPY)$ IBRX Anktiva was approved for a bladder cancer indication last week that triples their patient potential. Almost immediately a big pharma writer at Stat News came out with negative coverage, even though the data was better and adverse events were lower than Merck's Keytruda. Analysts have raised or reiterated price targets. Then today more unknown writers showed up with negative takes. After an early 5% gain, shorts attacked the bids and it closed down 1.20. Short interest was 34% this morning, trapped unless they used illegal tactics to sow doubt. This kind of attack slows funding for trials. The company should have been celebrated for the approval, but the negativity keeps coming. It is no wonder new drugs rarely succeed. If the boss at IBRX were not a multi-billionaire, they would have caught and killed the drug. Anyone wanting to short squeeze these scumbags, the price is $4 plus, below analyst targets today. Thanks for reading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
